AVIR · XBRL financial data

Atea Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (AVIR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	48,633	351,367	—	—	—	—
Research and development	38,023	167,205	81,936	114,243	144,101	148,024
General and administrative	21,640	45,785	48,714	49,919	48,849	32,863
Total operating expenses	59,663	212,990	130,650	164,162	192,950	180,887
Operating income (loss)	(11,030)	138,377	(130,650)	(164,162)	(192,950)	(180,887)
Income tax expense (benefit)	—	17,400	(3,590)	1,018	925	(6,162)
Net income (loss)	(10,947)	121,190	(115,909)	(135,956)	(168,385)	(158,349)
Earnings per share, basic USD per share	(0.51)	1.46	(1.39)	(1.63)	(2.00)	(1.94)
Earnings per share, diluted USD per share	(0.51)	1.37	(1.39)	(1.63)	(2.00)	(1.94)
Weighted average shares, basic thousands of shares	21,592	82,820	83,245	83,390	84,265	81,495
Weighted average shares, diluted thousands of shares	21,592	88,249	83,245	83,390	84,265	81,495

Fiscal years (AVIR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	850,117	764,375	188,460	143,823	64,696	95,713
Marketable securities	—	—	458,249	434,283	390,025	206,117
Marketable securities, non-current	—	—	0	0	0	—
Prepaid and other current assets	7,545	8,028	14,213	12,349	7,634	9,161
Total current assets	863,477	772,403	660,922	590,455	462,355	310,991
Property and equipment, net	48	23	1,705	1,289	873	457
Right-of-use asset	—	161	2,389	1,828	1,243	634
Total assets	863,632	772,892	666,708	594,968	464,668	315,218
Accounts payable	60	4,534	2,551	4,252	4,458	12,945
Total current liabilities	315,795	56,883	18,478	32,376	18,603	39,784
Lease liability, non-current	—	—	2,403	1,642	842	0
Total liabilities	315,831	62,815	26,136	39,776	25,801	39,784
Retained earnings (accumulated deficit)	(65,160)	56,030	(59,879)	(195,835)	(364,220)	(522,569)
Total stockholders' equity	547,801	710,077	640,572	555,192	438,867	275,434
Total liabilities and equity	863,632	772,892	666,708	594,968	464,668	315,218
Common shares outstanding (cover page) thousands of shares	82,737	83,226	83,342	84,165	85,525	79,672

Fiscal years (AVIR's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(10,947)	121,190	(115,909)	(135,956)	(168,385)	(158,349)
Stock-based compensation	7,457	39,621	46,718	49,428	51,767	20,720
Net cash from operating activities	296,734	(87,005)	(120,982)	(85,395)	(135,499)	(132,031)
Purchases of property and equipment	26	4	1,943	—	—	—
Net cash from investing activities	(26)	(4)	(455,410)	40,303	56,105	188,793
Proceeds from issuing common stock	27	1,465	—	—	—	—
Share repurchases	—	—	—	—	0	25,519
Net cash from financing activities	531,748	1,465	370	257	267	(25,745)
Net change in cash	828,456	(85,544)	(576,022)	(44,835)	(79,127)	31,017

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Atea Pharmaceuticals	76,548	not reported	(37,084)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	61,933	69,815	(28,435)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Tonix Pharmaceuticals Holding	176,232	13,544	(42,243)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Verastem	136,353	40,078	(43,909)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Corvus Pharmaceuticals	18,905	not reported	(15,398)*	84.1M	14.0 quarters	Q2 FY26 10-QJun 30, 2026
DBV Technologies	165,700	1,600	(51,500)*	314.4M	3.2 quarters	Q3 FY26 10-QSep 30, 2026
Ocugen	24,632	1,951	not reported	339.3M	—	Q3 FY26 10-QSep 30, 2026
Annexon	199,270	not reported	(48,007)*	not reported	4.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.